Filing Flows › Corcept Therapeutics (CORT) › Q1 2026
Corcept Therapeutics (CORT) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 30, 2026
Corcept Therapeutics (CORT) reported revenue of $165M for the first quarter 2026 (Q1 2026), +5% from a year earlier and -18% from the quarter before. Operating margin was -30.1%, net loss $31.8M (19.3% of revenue).
Corcept Therapeutics, Q1 2026: revenue $165M (+5% year over year), operating margin -30.1%, net loss $31.8M, operating cash flow −$16.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $165M | -18% | +5% |
| Operating profit | −$49.6M | -1205% | -1552% |
| Net earnings | −$31.8M | -231% | -255% |
| Operating cash flow | −$16.8M | -144% | -427% |
What changed
Revenue was $164.9M in Q1 2026, up 5% year over year and down 18% from the previous quarter.
Operating costs exceeded revenue by $49.6M, an operating margin of -30.1%. Total costs grew 39% against revenue growth of 5%. The fastest-growing cost line was SG&A (+60%). The quarter ended with a net loss of $31.8M, after a profit of $24.3M the previous quarter.
Operating cash flow was −$16.8M. Non-cash charges added back $598K of depreciation and amortization and $23.0M of share-based compensation. Working capital and other items used $8.7M. Capital expenditures of $201K exceeded it, leaving free cash flow of −$17.0M.
Questions
What was Corcept Therapeutics' revenue in the first quarter 2026?
Corcept Therapeutics (CORT) reported revenue of $165M for the first quarter 2026 (Q1 2026), +5% from a year earlier and -18% from the quarter before.
Was Corcept Therapeutics profitable in the first quarter 2026?
Operating loss was $49.6M (-30.1% of revenue) and net loss $31.8M.